Abstract:Cell-intrinsic reporters such as luciferase (LUC) and red fluorescent protein (RFP) have been commonly utilized in preclinical studies to image tumor growth and to monitor therapeutic responses. While extrinsic reporters that emit near infrared I (NIR-I: 650-950 nm) or near-infrared II (NIR-II: 1000 -1700 nm) optical signals have enabled minimization of tissue autofluorescence and light scattering, it has remained unclear as to whether their use has afforded more accurate tumor imaging in small animals. Here, we developed a novel optical imaging construct comprised of rare earth lanthanide nanoparticles coated with biodegradable diblock copolymers and doped with organic fluorophores, generating NIR-I and NIR-II emissive bands upon optical excitation. Simultaneous injection of multiple spectrally-unique nanoparticles into mice bearing tumor implants established via intraperitoneal dissemination of LUC+/ RFP+ OVCAR-8 ovarian cancer cells enabled direct comparisons of imaging with extrinsic vs. intrinsic reporters, NIR-II vs. NIR-I signals, as well as targeted vs. untargeted exogenous contrast agents in the same animal and over time. We discovered that in vivo optical imaging at NIR-II wavelengths facilitates more accurate detection of smaller and earlier tumor deposits, offering enhanced sensitivity, improved spatial contrast, and increased depths of tissue penetration as compared to imaging with visible or NIR-I fluorescent agents. Our work further highlights the hitherto underappreciated enhancements in tumor accumulation that may be achieved with intraperitoneal as opposed to intravenous administration of nanoparticles. Lastly, we found discrepancies in the fidelity of tumor uptake that could be obtained by utilizing small molecules for in vivo as opposed to in vitro targeting of nanoparticles to disseminated tumors. (C) 2017 Elsevier Ltd. All rights reserved.

In vivo near-infrared fluorescent optical imaging for CNS drug discovery

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications

Brain imaging with near-infrared fluorophores

Near-infrared fluorophores for biomedical imaging

Near-Infrared-II (NIR-II) Bioimaging via Off-Peak NIR-I Fluorescence Emission

Advanced near‐infrared light approaches for neuroimaging and neuromodulation

Recent Progress of Near-Infrared Fluorescence in vivo Bioimaging in the Second and Third Biological Window

Second Near‐Infrared (NIR‐II) Window for Imaging‐Navigated Modulation of Brain Structure and Function

Near-infrared luminescence high-contrast in vivo biomedical imaging

Advanced Fluorescence Imaging Technology in the Near-Infrared-II Window for Biomedical Applications

In vivo NIR-II fluorescence imaging for biology and medicine

Advances on <i>in vivo</i> Fluorescence Bioimaging in the Second Near-Infrared Window

Recent Advances in Second Near-Infrared Region (NIR-II) Fluorophores and Biomedical Applications

Progress of NIR-II fluorescence imaging technology applied to disease diagnosis and treatment

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

Recent advances in near-infrared II imaging technology for biological detection

Second near-infrared (NIR-II) imaging: a novel diagnostic technique for brain diseases

NIR‐II Fluorescence Imaging for Cerebrovascular Diseases

Real-Time and High-Resolution Bioimaging with Bright Aggregation-Induced Emission Dots in Short-Wave Infrared Region

Advances of NIR Light Responsive Materials for Diagnosis and Treatment of Brain Diseases